Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
Returns on capital
Theravance Biopharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
35.7%
avg 42.9%
ROIC
-2.4%
avg -45.6%
ROA
21.8%
avg -20.8%
Analysis
ROE is currently the strongest return metric at 35.7% versus its period average of 42.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Rick E. Winningham | Chief Executive Officer & Director | USD 1.47M | 66 | 0 | <0.01% |
Aine Miller | Senior Vice President of Development & Head of Ireland Office | USD 747.32K | 49 | 0 | <0.01% |
Brett A. Grimaud | Senior Vice President, General Counsel & Secretary | USD 690.87K | 52 | 0 | <0.01% |
Rhonda F. Farnum | Chief Business Officer and Senior Vice President of Commercial & Medical Affairs | USD 682.94K | 61 | — | — |
Aziz Sawaf | Senior VP of Operations Strategy & CFO | USD 660.15K | 44 | 0 | <0.01% |
Stuart Knight | Senior Vice President of IT&I and Chief Information Officer | — | — | — | — |
Stacy L. Pryce | Senior Vice President & Chief Strategy Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$7.84M
Net Transaction Value
−$7.84M
Net selling
Most Active
Farnum Rhonda
12 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 15, 26Sep 15, 2026 | Farnum Rhonda Direct | Sell | $56.7K$56,706.52 |
| Sep 15, 26Sep 15, 2026 | Farnum Rhonda Direct | Sell | $56.7K$56,690.15 |
| Sep 15, 26Sep 15, 2026 | Farnum Rhonda Direct | Sell | $113.4K$113,396.67 |
| Jul 1, 26Jul 1, 2026 | Samaha Eli Indirect | Sell | $642.6K$642,628.36 |
| Jun 30, 26Jun 30, 2026 | Samaha Eli Indirect | Sell | $428.8K$428,787.59 |
| Jun 29, 26Jun 29, 2026 | Samaha Eli Indirect | Sell | $4.7M$4,720,139.30 |
| Jun 15, 26Jun 15, 2026 | Farnum Rhonda Direct | Sell | $54.6K$54,562.98 |
| Jun 15, 26Jun 15, 2026 | Farnum Rhonda Direct | Sell | $54.5K$54,525.29 |
| Jun 15, 26Jun 15, 2026 | Farnum Rhonda Direct | Sell | $109.1K$109,078.94 |
| Mar 16, 26Mar 16, 2026 | Farnum Rhonda Direct | Sell | $108.1K$108,087.90 |
1–10 of 17
Summary
Insiders reported 0 buys worth $0.00 and 17 sells worth $7.84M over the last 12 months. That adds up to net selling of $7.84M. Farnum Rhonda was the most active insider with 12 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -4.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +27.9% | +1.2% (5yr)2 analysts |
| Net Income | N/A | N/A | -50.5% | -4.4% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.9% over three years. Forward estimates point to Revenue at +1.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Theravance Biopharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about TBPH's management, answered from reported figures.
Who manages TBPH?
Theravance Biopharma, Inc. (TBPH) lists 7 active executives. The top listed executive is Aziz Sawaf, Senior VP of Operations Strategy & CFO.
Are TBPH insiders buying or selling?
Recent insider activity shows net selling of $27.59M.
Continue the stock analysis
Jump to another research area for this company.